Relevance exists between tumorigenesis and embryonic development. Distinct clinical and molecular features, as well as the relationship between the pattern of lymphoma invasion and germ layer development remain largely unknown. Researchers identified a germ layer-dependent specification of extranodal invasion (ENI) in diffuse large B-cell lymphoma. Upon R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) treatment, mesoderm-originating ENI (ENI-mesoderm) was significantly associated with inferior progression-free survival and overall survival, as compared to ectoderm-originating ENI (ENI-ectoderm) and endoderm-originating ENI (ENI-endoderm). Representative oncogenic mutations were MYD88, PIM1, and TBL1XR1 in ENI-ectoderm, TP53 and TET2 in ENI-endoderm, and MYD88, PIM1, TBL1XR1, and CD79B in ENI-mesoderm. Notably, organotrophic migration exhibited temporal disparities corresponding to germ layer development, occurring from ectoderm- to endoderm- and mesoderm-originating organs, with a similar trajectory to the germ layer process. Single-cell RNA sequencing revealed that malignant B cells follow a developmental trajectory mirroring the germ layer process, differentiating from a progenitor state enriched with NF-κB and T-cell activation signaling into two distinct branches by either upregulated B-cell receptor signaling (Path I) or sustained T-cell activation (Path II). Regarding immune checkpoints, ENI-ectoderm, ENI-endoderm, and ENI-mesoderm exhibited significant upregulation of LGALS9, PD-L1, and B7-H3, respectively. Their findings thus contributed to a better understanding of crosstalk between lymphoma progression and embryonic development, providing new insights into targeted approaches against germ layer-dependent invasion in cancer treatment.

When in life we gain weight can have a significant impact on our health many years later. In a study involving over 600,000 people, researchers at Lund University in Sweden have investigated how changes in weight between the ages of 17 and 60 are linked to the risk of dying from various diseases. The results show a clear pattern: weight gain early in adulthood has the greatest impact. 

Researchers at ITQB NOVA, in collaboration with IPO Lisboa, will seek new biomarkers to monitor the progression of the most aggressive types of breast cancer and help personalize treatment by studying how tumors “shut down” the immune system.

Researchers at Oregon Health & Science University have uncovered a key reason why immunotherapy has largely failed in pancreatic cancer — and identified a promising strategy to overcome that resistance. 

The study, published in the journal Immunity, shows that pancreatic tumors actively reshape their immune environment by co‑opting regulatory immune cells that normally shut down tumor-killing cells. By reprogramming those cells, the research reveals a potential pathway to make immunotherapy effective against one of the deadliest and most treatment‑resistant cancers. 

Breast cancer (BCA) is one of the most common cancers worldwide, with a high rate of mortality and morbidity in women. This review focuses on the applications of nanotechnology, nanomaterials, and nanoparticles (NPs) in BCA, encompassing diagnosis and therapy. Nanotechnologies, nanocarriers, and nano-encapsulations versus their corresponding counterparts for BCA diagnosis and therapy have been discussed. Various drug formulations into different nanocarriers (lipid NPs, nanoemulsions, polymeric NPs, and metal-based NPs) enhanced their bioavailability and therapeutic efficacy, overcoming the limitations of conventional formulations. Additionally, clinical specialists have achieved improved outcomes in the detection and monitoring of BCA at various stages using nanotechnology, ultimately leading to an improved quality of life for patients.